Contact
Please use this form to send email to PR contact of this press release:
Hudson Therapeutics Announces Completion of Phase 2b Part 1 Clinical Trial for Nugel
TO:
Ellie Jung
Hudson Therapeutics, Inc, US Subsidiary of Shaperon